Ryan B Corcoran's Breakthrough: Conquering GI Cancer Drug Resistance
The Elusive Nature of Gastrointestinal Cancer Drug Resistance Gastrointestinal (GI) cancers, encompassing cancers of the colon, pancreas, and other organs, present a significant clinical challenge due to their propensity to develop resistance to targeted therapies. Initially, these therapies, often employing precision-guided mechanisms, yield impressive results. However, GI cancers demonstrate remarkable adaptability, evolving resistance mechanisms that diminish the efficacy of these treatments. This resistance significantly compromises treatment success, highlighting the urgent need for innovative approaches....